<DOC>
	<DOC>NCT01571596</DOC>
	<brief_summary>The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).</brief_summary>
	<brief_title>An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<criteria>1. Satisfactory completion of KKP's sponsored KRN23INT001 clinical trial 2. eGFR â‰¥ 60 mL/min 3. Corrected Ca &lt; 10.8 mg/dL 4. For female of childbearing potential, a negative serum pregnancy test 5. A willingness to utilize adequate contraception and not become pregnant [or to have their partner(s) become pregnant] during the study 6. Additional inclusion criteria apply 1. Subject experienced a safetyrelated event in the KRN23INT001 study 2. Pregnant or lactating female subject or pregnant or female planning to become pregnant during the study 3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the course of the KRN23INT001 study and/or of this study 4. Condition which could present a concern for either the subject's safety or difficulty with data interpretation 5. Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>XLH</keyword>
</DOC>